Temporal Trends in Antiplatelet/Antithrombotic Use in Acute Coronary Syndromes and In-Hospital Major Bleeding Complications

Apurva A. Motivala, Umesh Tamhane, Fadi Saab, Jin Li, Eva Kline Rogers, James Froehlich, Mauro Moscucci, Kim A. Eagle, Hitinder S. Gurm

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Antithrombotic and antiplatelet agents are essential for the management of patients with acute coronary syndromes (ACSs). These pharmacologic agents have the potential for increased risk of bleeding. It is not clear if the increased uptake of these therapies has resulted in a clinically evident increase in bleeding complications over time. In this study, we included 3,193 consecutive patients who were admitted to the University of Michigan with an ACS (unstable angina or myocardial infarction) between January 1999 and December 2004. These patients were analyzed for temporal trends in antithrombotic and antiplatelet agent use, thrombolytic therapy, cardiac catheterizations, percutaneous coronary interventions, and major bleeding complications (including gastrointestinal, vascular access, and intracranial hemorrhage). We found a decreasing temporal trend in the incidence of major in-hospital bleeding complications (p <0.001) despite an increasing use of ticlopidine/clopidogrel (p <0.0001), unfractionated heparin (p <0.01), glycoprotein IIb/IIIa inhibitors (p <0.0001), and percutaneous coronary intervention (p <0.0001) in the management of patients with ACSs. In conclusion, major bleeding remains a significant complication of ACS management but has decreased significantly over time. We believe that this decreasing bleeding trend may be because of better identification of higher risk patients, attention to correct dosing, appropriate monitoring, and incorporation of various periprocedural strategies in routine clinical practice.

Original languageEnglish
Pages (from-to)1359-1363
Number of pages5
JournalAmerican Journal of Cardiology
Volume100
Issue number9
DOIs
StatePublished - Nov 1 2007

Fingerprint

Acute Coronary Syndrome
Hemorrhage
Fibrinolytic Agents
clopidogrel
Platelet Aggregation Inhibitors
Percutaneous Coronary Intervention
Ticlopidine
Platelet Glycoprotein GPIIb-IIIa Complex
Intracranial Hemorrhages
Thrombolytic Therapy
Unstable Angina
Cardiac Catheterization
Blood Vessels
Heparin
Myocardial Infarction
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Temporal Trends in Antiplatelet/Antithrombotic Use in Acute Coronary Syndromes and In-Hospital Major Bleeding Complications. / Motivala, Apurva A.; Tamhane, Umesh; Saab, Fadi; Li, Jin; Rogers, Eva Kline; Froehlich, James; Moscucci, Mauro; Eagle, Kim A.; Gurm, Hitinder S.

In: American Journal of Cardiology, Vol. 100, No. 9, 01.11.2007, p. 1359-1363.

Research output: Contribution to journalArticle

Motivala, AA, Tamhane, U, Saab, F, Li, J, Rogers, EK, Froehlich, J, Moscucci, M, Eagle, KA & Gurm, HS 2007, 'Temporal Trends in Antiplatelet/Antithrombotic Use in Acute Coronary Syndromes and In-Hospital Major Bleeding Complications', American Journal of Cardiology, vol. 100, no. 9, pp. 1359-1363. https://doi.org/10.1016/j.amjcard.2007.06.023
Motivala, Apurva A. ; Tamhane, Umesh ; Saab, Fadi ; Li, Jin ; Rogers, Eva Kline ; Froehlich, James ; Moscucci, Mauro ; Eagle, Kim A. ; Gurm, Hitinder S. / Temporal Trends in Antiplatelet/Antithrombotic Use in Acute Coronary Syndromes and In-Hospital Major Bleeding Complications. In: American Journal of Cardiology. 2007 ; Vol. 100, No. 9. pp. 1359-1363.
@article{8d6a2e06fe884fe4af615bb573251689,
title = "Temporal Trends in Antiplatelet/Antithrombotic Use in Acute Coronary Syndromes and In-Hospital Major Bleeding Complications",
abstract = "Antithrombotic and antiplatelet agents are essential for the management of patients with acute coronary syndromes (ACSs). These pharmacologic agents have the potential for increased risk of bleeding. It is not clear if the increased uptake of these therapies has resulted in a clinically evident increase in bleeding complications over time. In this study, we included 3,193 consecutive patients who were admitted to the University of Michigan with an ACS (unstable angina or myocardial infarction) between January 1999 and December 2004. These patients were analyzed for temporal trends in antithrombotic and antiplatelet agent use, thrombolytic therapy, cardiac catheterizations, percutaneous coronary interventions, and major bleeding complications (including gastrointestinal, vascular access, and intracranial hemorrhage). We found a decreasing temporal trend in the incidence of major in-hospital bleeding complications (p <0.001) despite an increasing use of ticlopidine/clopidogrel (p <0.0001), unfractionated heparin (p <0.01), glycoprotein IIb/IIIa inhibitors (p <0.0001), and percutaneous coronary intervention (p <0.0001) in the management of patients with ACSs. In conclusion, major bleeding remains a significant complication of ACS management but has decreased significantly over time. We believe that this decreasing bleeding trend may be because of better identification of higher risk patients, attention to correct dosing, appropriate monitoring, and incorporation of various periprocedural strategies in routine clinical practice.",
author = "Motivala, {Apurva A.} and Umesh Tamhane and Fadi Saab and Jin Li and Rogers, {Eva Kline} and James Froehlich and Mauro Moscucci and Eagle, {Kim A.} and Gurm, {Hitinder S.}",
year = "2007",
month = "11",
day = "1",
doi = "10.1016/j.amjcard.2007.06.023",
language = "English",
volume = "100",
pages = "1359--1363",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Temporal Trends in Antiplatelet/Antithrombotic Use in Acute Coronary Syndromes and In-Hospital Major Bleeding Complications

AU - Motivala, Apurva A.

AU - Tamhane, Umesh

AU - Saab, Fadi

AU - Li, Jin

AU - Rogers, Eva Kline

AU - Froehlich, James

AU - Moscucci, Mauro

AU - Eagle, Kim A.

AU - Gurm, Hitinder S.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Antithrombotic and antiplatelet agents are essential for the management of patients with acute coronary syndromes (ACSs). These pharmacologic agents have the potential for increased risk of bleeding. It is not clear if the increased uptake of these therapies has resulted in a clinically evident increase in bleeding complications over time. In this study, we included 3,193 consecutive patients who were admitted to the University of Michigan with an ACS (unstable angina or myocardial infarction) between January 1999 and December 2004. These patients were analyzed for temporal trends in antithrombotic and antiplatelet agent use, thrombolytic therapy, cardiac catheterizations, percutaneous coronary interventions, and major bleeding complications (including gastrointestinal, vascular access, and intracranial hemorrhage). We found a decreasing temporal trend in the incidence of major in-hospital bleeding complications (p <0.001) despite an increasing use of ticlopidine/clopidogrel (p <0.0001), unfractionated heparin (p <0.01), glycoprotein IIb/IIIa inhibitors (p <0.0001), and percutaneous coronary intervention (p <0.0001) in the management of patients with ACSs. In conclusion, major bleeding remains a significant complication of ACS management but has decreased significantly over time. We believe that this decreasing bleeding trend may be because of better identification of higher risk patients, attention to correct dosing, appropriate monitoring, and incorporation of various periprocedural strategies in routine clinical practice.

AB - Antithrombotic and antiplatelet agents are essential for the management of patients with acute coronary syndromes (ACSs). These pharmacologic agents have the potential for increased risk of bleeding. It is not clear if the increased uptake of these therapies has resulted in a clinically evident increase in bleeding complications over time. In this study, we included 3,193 consecutive patients who were admitted to the University of Michigan with an ACS (unstable angina or myocardial infarction) between January 1999 and December 2004. These patients were analyzed for temporal trends in antithrombotic and antiplatelet agent use, thrombolytic therapy, cardiac catheterizations, percutaneous coronary interventions, and major bleeding complications (including gastrointestinal, vascular access, and intracranial hemorrhage). We found a decreasing temporal trend in the incidence of major in-hospital bleeding complications (p <0.001) despite an increasing use of ticlopidine/clopidogrel (p <0.0001), unfractionated heparin (p <0.01), glycoprotein IIb/IIIa inhibitors (p <0.0001), and percutaneous coronary intervention (p <0.0001) in the management of patients with ACSs. In conclusion, major bleeding remains a significant complication of ACS management but has decreased significantly over time. We believe that this decreasing bleeding trend may be because of better identification of higher risk patients, attention to correct dosing, appropriate monitoring, and incorporation of various periprocedural strategies in routine clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=35348925013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348925013&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2007.06.023

DO - 10.1016/j.amjcard.2007.06.023

M3 - Article

C2 - 17950790

AN - SCOPUS:35348925013

VL - 100

SP - 1359

EP - 1363

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -